Pasar al contenido principal

BIOMARCADORES EN EXOSOMAS PLASMATICOS PARA EL DIAGNOSTICO TEMPRANO DE LA ENFERMEDAD DE ALZHEIMER PRODROMICA

PID2021-122473OA-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACIO ACE INSTITUT CATALA DE NEUROCIENCIES APLICADES

Resultados relacionados

Resultados totales (Incluyendo duplicados): 13
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Clinical value of plasma pTau181 to predict Alzheimer's disease pathology in a large real-world cohort of a memory clinic

  • Cano, Amanda|||0000-0001-9567-4283
  • Capdevila, María
  • Puerta, Raquel|||0000-0002-1191-5893
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Montrreal Navarro, Laura|||0000-0002-0010-645X
  • De Rojas, Itziar|||0000-0002-2148-381X
  • García-González, Pablo|||0000-0003-0125-5403
  • Olivé Roig, Clàudia|||0000-0002-9438-5639
  • García-Gutiérrez, Fernando
  • Sotolongo Grau, Oscar|||0000-0002-9679-0670
  • Orellana del Río, Adelina|||0000-0002-0204-1944
  • Aguilera, Nuria
  • Ramis, Maribel
  • Rosende-Roca, Maite
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
  • Tartari, Juan Pablo
  • Lafuente, Asunción
  • Vargas, Liliana|||0000-0001-5685-5903
  • Pérez-Cordón, Alba|||0000-0002-6028-0791
  • Muñoz, Nathalia
  • Sanabria, Ángela|||0000-0002-7501-9895
  • Alegret, Montserrat|||0000-0002-8164-9500
  • Morató, Xavier|||0000-0002-3012-2864
  • Tárraga, Lluís|||0000-0002-8423-946X
  • Fernández, Victoria
  • Marquié, Marta|||0000-0002-0660-0950
  • Valero, Sergi|||0000-0002-6599-948X
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Boada, Mercè|||0000-0003-2617-3009
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
The identification of patients with an elevated risk of developing Alzheimer's disease (AD) dementia and eligible for the disease-modifying treatments (DMTs) in the earliest stages is one of the greatest challenges in the clinical practice. Plasma biomarkers has the potential to predict these issues, but further research is still needed to translate them to clinical practice. Here we evaluated the clinical applicability of plasma pTau181 as a predictive marker of AD pathology in a large real-world cohort of a memory clinic. Methods: Three independent cohorts (modelling [n = 991, 59.7% female], testing [n = 642, 56.2% female] and validation [n = 441, 55.1% female]) of real-world patients with subjective cognitive decline (SCD), mild cognitive impairment (MCI), AD dementia, and other dementias were included. Paired cerebrospinal fluid (CSF) and plasma samples were used to measure AT(N) CSF biomarkers and plasma pTau181. CSF and plasma pTau181 showed correlation in all phenotypes except in SCD and other dementias. Age significantly influenced the biomarker's performance. The general Aβ(+) vs Aβ(-) ROC curve showed an AUC = 0.77 [0.74-0.80], whereas the specific ROC curve of MCI due to AD vs non-AD MCI showed an AUC = 0.89 [0.85-0.93]. A cut-off value of 1.30 pg/ml of plasma pTau181 exhibited a sensitivity of 93.57% [88.72-96.52], specificity of 72.38% [62.51-79.01], VPP of 77.85% [70.61-83.54], and 8.30% false negatives in the subjects with MCI of the testing cohort. The HR of cox regression showed that patients with MCI up to this cut-off value exhibited a HR = 1.84 [1.05-3.22] higher risk to convert to AD dementia than patients with MCI below the cut-off value. Plasma pTau181 has the potential to be used in the memory clinics as a screening biomarker of AD pathology in subjects with MCI, presenting a valuable prognostic utility in predicting the MCI conversion to AD dementia. In the context of a real-world population, a confirmatory test employing gold-standard procedures is still advisable. This study has been mainly funded by Ace Alzheimer Center Barcelona, Instituto de Salud Carlos III (ISCIII), Biomedical Research Networking Centre in Neurodegenerative Diseases (CIBERNED), Spanish Ministry of Science and Innovation, Fundación ADEY, Fundación Echevarne and Grífols S.A.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Electrochemical biosensor for early Alzheimer's detection and patient risk stratification using plasma exosomes

  • Rossi, Rosanna|||0000-0002-3656-2908
  • Cano, Amanda|||0000-0001-9567-4283
  • Pallarès-Rusiñol, Arnau|||0000-0001-9990-148X
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
  • Martí, Mercè|||0000-0002-1846-0043
  • Pividori, María Isabel|||0000-0002-5266-7873
Alzheimer's Disease (AD) is the leading cause of dementia, accounting for 60-70 % of cases worldwide. Early diagnosis remains challenging due to the limitations of current diagnostic tools, which are costly, invasive, and suffer from low patient compliance. Blood-based biomarkers, particularly plasma brain-derived exosomes (BDEs), have emerged as a promising alternative since they carry AD-related molecules and can be isolated non-invasively. In this study, an immunoassay was developed to isolate BDEs using magnetic particles functionalized with an anti-neuroligin-3 (NLGN3) antibody, while the AD-related marker β-secretase (BACE-1) was detected on the captured exosomes. This is the first report combining NLGN3 for for the isolation of BDEs with BACE-1 as a detection target, establishing a novel biomarker panel for AD diagnostics. The assay was evaluated across three readout platforms-optical, chemiluminescent, and electrochemical-with detection limits in the range of 104-105 exosomes μL-1. Among them, the portable electrochemical platform achieved the improved LOD (1.51 × 104 exosomes μL-1, R2 = 0.9829). Plasma samples from patients with AD, mild cognitive impairment (MCI), and healthy controls were analyzed, revealing differences in exosomal BACE-1 levels (p < 0.1, t-test). These findings demonstrate, for the first time, an in vitro diagnostic approach based on a portable electrochemical biosensor for early AD detection in plasma through a novel exosomal biomarker panel. Compared to conventional diagnostics, this biosensor offers a non-invasive and cost-effective solution for AD screening, with the potential to support earlier intervention and patient risk stratification.
Dipòsit Digital de Documents de la UAB
Publicación Artículo preliminar (WorkingPaper)

A peripheral proteomic signature of Alzheimer's disease is identified in the plasma extracellular vesicles of mild cognitive impairment patients from a memory clinic, the BIOPEXAL study

  • Capdevila-Bayo, Maria
  • Rossi, Rosanna|||0000-0002-3656-2908
  • De Rojas, Itziar|||0000-0002-2148-381X
  • Puerta, Raquel|||0000-0002-1191-5893
  • Guzman, Laura
  • Carrasco Exposito, Marina|||0000-0001-8301-8000
  • Muñoz-Morales, Álvaro
  • Olivé Roig, Clàudia|||0000-0002-9438-5639
  • Montrreal Navarro, Laura|||0000-0002-0010-645X
  • García-González, Pablo|||0000-0003-0125-5403
  • Bayón-Buján, Paula
  • Miguel-Romero, Andrea
  • Calm, Berta
  • Sotolongo Grau, Oscar|||0000-0002-9679-0670
  • Orellana del Río, Adelina|||0000-0002-0204-1944
  • Tatinya, Natalia
  • Martínez, Marta
  • Alegret, Montserrat|||0000-0002-8164-9500
  • Sanz Cartagena, Mª Pilar
  • Fernández, Mª Victoria
  • Marquié, Marta|||0000-0002-0660-0950
  • Valero, Sergi|||0000-0002-6599-948X
  • Montalban, Xavier|||0000-0002-0098-9918
  • Camins, Antoni|||0000-0002-1229-5956
  • Ramírez-Reveco, Alfredo|||0000-0003-4782-4261
  • Martí, Mercè|||0000-0002-1846-0043
  • Pividori, María Isabel|||0000-0002-5266-7873
  • Boada, Mercè|||0000-0003-2617-3009
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
  • Ettcheto, Miren|||0000-0002-4301-7297
  • Cano, Amanda|||0000-0001-9567-4283
Aims: Alzheimer's disease (AD) is commonly diagnosed when neuronal damage is already established and irreversible. Achieving an accurate differential diagnosis in the preclinical and mild cognitive impairment (MCI) stage is one of the greatest challenges nowadays. Nanotechnological analysis of plasma extracellular vesicles (pEVs) are gaining attention as a promising tool for the early detection of AD pathology. This study aims to evaluate the proteomic profile of pEVs from patients with MCI and AD dementia to explore their potential as AD screening tools. Methods: pEVs were isolated by ultracentrifugation from 144 patients with MCI A-T-, MCI A+T+, and AD dementia. Nanoparticle tracking analysis and cryo-TEM were used to characterize the pEVs. CSF, serum and pEVs proteomics were carried out by using the multiplex PEA technology of Olink® proteomics, Inflammation and Neurology Explore 384 panels (768 proteins). Results: Characterization results showed that isolated plasma fraction corresponded in shape, size and concentration to EVs. Many pEVs neurology proteins involved in AD pathology significantly correlated (r > ± 0.30, p < 0.05) with their CSF homonyms, but not with their serum's. pEVs' proteome correlated with common AD signatures (CSF Aβ42 and pTau181, plasma pTau181, MMSE, NBACE, and Qalb) showing similar patterns to those observed with CSF biomarkers. Several pEVs neurology proteins didn't exhibit differences between the MCI A+T+ and AD dementia groups, whilst they did with MCI A-T-. Proteins in pEVs showed strong correlations with several measures of brain atrophy in MRI. Several neurology pEV proteins predicted conversion from MCI to AD dementia. Moreover, some of these showed a significant diagnostic accuracy of AD pathology. Conclusion: Preliminary results suggest that EVs biomarker signature could reflect AD pathology in the prodromal stages of AD continuum. However, further experiments are still needed for a better understanding of EVs' role in AD development and pathology dissemination.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Harnessing acoustic speech parameters to decipher amyloid status in individuals with mild cognitive impairment

  • García-Gutiérrez, Fernando
  • Hinzen, Wolfram
  • Valero, Sergi
Alzheimer's disease (AD) is a neurodegenerative condition characterized by a gradual decline in cognitive functions. Currently, there are no effective treatments for AD, underscoring the importance of identifying individuals in the preclinical stages of mild cognitive impairment (MCI) to enable early interventions. Among the neuropathological events associated with the onset of the disease is the accumulation of amyloid protein in the brain, which correlates with decreased levels of Aß42 peptide in the cerebrospinal fluid (CSF). Consequently, the development of non-invasive, low-cost, and easy-to-administer proxies for detecting Aß42 positivity in CSF becomes particularly valuable. A promising approach to achieve this is spontaneous speech analysis, which combined with machine learning (ML) techniques, has proven highly useful in AD. In this study, we examined the relationship between amyloid status in CSF and acoustic features derived from the description of the Cookie Theft picture in MCI patients from a memory clinic. The cohort consisted of fifty-two patients with MCI (mean age 73 years, 65% female, and 57% positive amyloid status). Eighty-eight acoustic parameters were extracted from voice recordings using the extended Geneva Minimalistic Acoustic Parameter Set (eGeMAPS), and several ML models were used to classify the amyloid status. Furthermore, interpretability techniques were employed to examine the influence of input variables on the determination of amyloid-positive status. The best model, based on acoustic variables, achieved an accuracy of 75% with an area under the curve (AUC) of 0.79 in the prediction of amyloid status evaluated by bootstrapping and Leave-One-Out Cross Validation (LOOCV), outperforming conventional neuropsychological tests (AUC = 0.66). Our results showed that the automated analysis of voice recordings derived from spontaneous speech tests offers valuable insights into AD biomarkers during the preclinical stages. These findings introduce novel possibilities for the use of digital biomarkers to identify subjects at high risk of developing AD., This project has received funding from R&D Missions in the Artificial Intelligence program, which is part of the Spain Digital 2025 Agenda and the National Artificial Intelligence Strategy and financed by the European Union through Next Generation EU funds (project TARTAGLIA, exp. MIA.2021.M02.0005). This project has also received funding from the Instituto de Salud Carlos III (ISCIII) Acción Estratégica en Salud, integrated in the Spanish National RCDCI Plan and financed by ISCIII Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER - Una manera de hacer Europa) grant PI19/00335 awarded to MM, grant PI17/01474 awarded to MB, grants AC17/00100, PI19/01301, and PI22/01403 awarded to AR and by the European Union Joint Programme-Neurodegenerative Disease Research (JPND) Multinational research projects on Personalized Medicine for Neurodegenerative Diseases/Instituto de Salud Carlos III grant AC19/00097 awarded to AR and grant FI20/00215 from the Instituto de Salud Carlos III (ISCIII) awarded to IR. For CSF biomarker research, AR and MB received support from the European Union/EFPIA Innovative Medicines Initiative Joint undertaking ADAPTED and MOPEAD projects (grant numbers 115975 and 115985, respectively). AC received support from the Instituto de Salud Carlos III (ISCIII) under the grant Sara Borrell (CD22/00125) and the Spanish Ministry of Science and Innovation, Proyectos de Generación de Conocimiento grant PID2021-122473OA-I00.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Correlations between the NMR Lipoprotein Profile, APOE Genotype, and Cholesterol Efflux Capacity of Fasting Plasma from Cognitively Healthy Elderly Adults

  • Rojas, Itziar de
  • Barrio, Laura
  • Hernández, Isabel
  • Montrreal, Laura
  • García-González, Pablo
  • Marquié, Marta
  • Valero, Sergi
  • Cano, Amanda
  • Orellana, Adelina
  • Boada, Mercè
  • Mañes, Santos
  • Ruiz, Agustín
Cholesterol efflux capacity (CEC) is of interest given its potential relationship with several important clinical conditions including Alzheimer's disease. The inactivation of the APOE locus in mouse models supports the idea that it is involved in determining the CEC. With that in mind, we examine the impact of the plasma metabolome profile and the APOE genotype on the CEC in cognitively healthy elderly subjects. The study subjects were 144 unrelated healthy individuals. The plasma CEC was determined by exposing cultured mouse macrophages treated with BODIPY-cholesterol to human plasma. The metabolome profile was determined using NMR techniques. Multiple regression was performed to identify the most important predictors of CEC, as well as the NMR features most strongly associated with the APOE genotype. Plasma 3-hydroxybutyrate was the variable most strongly correlated with the CEC (r = 0.365; p = 7.3 × 10-6). Male sex was associated with a stronger CEC (r = -0.326, p = 6.8 × 10-5). Most of the NMR particles associated with the CEC did not correlate with the APOE genotype. The NMR metabolomics results confirmed the APOE genotype to have a huge effect on the concentration of plasma lipoprotein particles as well as those of other molecules including omega-3 fatty acids. In conclusion, the CEC of human plasma was associated with ketone body concentration, sex, and (to a lesser extent) the other features of the plasma lipoprotein profile. The APOE genotype exerted only a weak effect on the CEC via the modulation of the lipoprotein profile. The APOE locus was associated with omega-3 fatty acid levels independent of the plasma cholesterol level., A.R. and S.M. are funded by the Innovative Medicines Initiative 2 Joint Undertaking, which receives support from the European Union Horizon 2020 Research And Innovation Programme (ADAPTED grant no. 115975). S.M.’s research is also funded by the Spanish Ministry of Science and Innovation (PID2020-116303RB-I00/MCIN/AEI/10.13039/501100011033). A.R.’s research is also supported by Instituto de Salud Carlos III (ISCIII) via grants PI13/02434, PI16/01861, PI19/01301, and PI22/01403 Acción Estratégica en Salud, within the framework of the Spanish National R+D+I Plan and funded by the ISCIII-Subdirección General de Evaluación and the European Regional Development Fund (EDRF), as well as by the JPco-fuND-2 “Multinational Research Projects on Personalized Medicine for Neurodegenerative Diseases” PREADAPT project. I.d.R. is supported by a national grant from the Instituto de Salud Carlos III (ISCIII) FI20/00215. M.M. receives support from Instituto de Salud Carlos III (ISCIII) via grant PI19/00335 Acción Estratégica en Salud, within the framework of the Spanish National R+D+I Plan and funded by ISCIII-Subdirección General de Evaluación and the EDRF. AC acknowledges the support of the Instituto de Salud Carlos III (ISCIII) grant Sara Borrell (CD22/00125) and Ministerio de Ciencia e Innovación, Proyectos de Generación de Conocimiento grant PID2021-122473OA-I00. Fundacio ACE researchers research receives support from Grifols, Roche, Janssen, Life Molecular Imaging, Araclon Biotech, Alkahest, Laboratorio de Análisis Echevarne, and IrsiCaixa., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

Connecting genomic and proteomic signatures of amyloid burden in the brain

  • Puerta, Raquel
  • de Rojas, Itziar
  • García-González, Pablo
  • Olivé-Roig, Claudia
  • Sotolongo-Grau, Oscar
  • García-Sánchez, Ainhoa
  • García-Gutiérrez, Fernando
  • Montrreal, Laura
  • Tartari, Juan Pablo
  • Sanabria, Ángela
  • Pytel, Vanesa
  • Lage, Carmen
  • Quintela, Ines
  • Aguilera, Nuria
  • Rodríguez-Rodríguez, Eloy
  • Alarcón-Martín, Emilio
  • Orellana, Adelina
  • Pastor, Pau
  • Pérez-Tur, Jordi
  • Pinol-Ripoll, Gerard
  • López de Munain, Adolfo
  • García-Alberca, José María
  • Royo, José Luis
  • Bullido, María Jesús
  • Álvarez, Victoria
  • Real, Luis Miguel
  • Corbatón Anchuelo, Arturo
  • Gómez-Garre, Dulcenombre
  • Martínez Larrad, María Teresa
  • Franco-Macias, Emilio
  • Mir, Pablo
  • Medina, Miguel
  • Sánchez-Valle, Raquel
  • Icardo, Oriol
  • Dols-Sáez, María Eugenia
  • Carracedo, Ángel
  • Tárraga, Lluís
  • Alegret, Montse
  • Valero, Sergi
  • Marquie, Marta
  • Boada, Mercè
  • Juan, Pascual
  • Sánchez Cavazos, José Enrique
  • Cabrera, Alfredo
  • Cano, Amanda
  • Ruiz, Agustín
preprint 42 páginas, 6 figuras, 2 tablas, Background: Alzheimer's disease (AD) has a high heritable component characteristic of complex diseases, yet many of the genetic risk factors remain unknown. We combined genome-wide association studies (GWAS) on amyloid endophenotypes measured in cerebrospinal fluid (CSF) and positron emission tomography (PET) as surrogates of amyloid pathology, which may be helpful to understand the underlying biology of the disease. Methods: We performed a meta-analysis of GWAS of CSF Aβ42 and PET measures combining six independent cohorts (n=2,076). Due to the opposite effect direction of Aβ phenotypes in CSF and PET measures, only genetic signals in the opposite direction were considered for analysis (n=376,599). Polygenic risk scores (PRS) were calculated and evaluated for AD status and amyloid endophenotypes. We then searched the CSF proteome signature of brain amyloidosis using SOMAscan proteomic data (Ace cohort, n=1,008) and connected it with GWAS results of loci modulating amyloidosis. Finally, we compared our results with a large meta-analysis using publicly available datasets in CSF (n=13,409) and PET (n=13,116). This combined approach enabled the identification of overlapping genes and proteins associated with amyloid burden and the assessment of their biological significance using enrichment analyses. Results: After filtering the meta-GWAS, we observed genome-wide significance in the rs429358-APOE locus and nine suggestive hits were annotated. We replicated the APOE loci using the large CSF-PET meta-GWAS and identified multiple AD-associated genes as well as the novel GADL1 locus. Additionally, we found a significant association between the AD PRS and amyloid levels, whereas no significant association was found between any Aβ PRS with AD risk. CSF SOMAscan analysis identified 1,387 FDR-significant proteins associated with CSF Aβ42 levels. The overlap among GWAS loci and proteins associated with amyloid burden was very poor (n=35). The enrichment analysis of overlapping hits strongly suggested several signalling pathways connecting amyloidosis with the anchored component of the plasma membrane, synapse physiology and mental disorders that were replicated in the large CSF-PET meta-analysis. Conclusions: The strategy of combining CSF and PET amyloid endophenotypes GWAS with CSF proteome analyses might be effective for identifying signals associated with the AD pathological process and elucidate causative molecular mechanisms behind the amyloid mobilization in AD., The Genome Research @ Ace Alzheimer Center Barcelona project (GR@ACE) is supported by Grifols SA, Fundación bancaria 'La Caixa', Ace Alzheimer Center Barcelona and CIBERNED. Ace Alzheimer Center Barcelona is one of the participating centers of the Dementia Genetics Spanish Consortium (DEGESCO). The FACEHBI study is supported by funds from Ace Alzheimer Center Barcelona, Grifols, Life Molecular Imaging, Araclon Biotech, Alkahest, Laboratorio de análisis Echevarne and IrsiCaixa. Authors acknowledge the support of the Spanish Ministry of Science and Innovation, Proyectos de Generación de Conocimiento grants PID2021-122473OA-I00, PID2021-123462OB-I00 and PID2019-106625RB-I00. ISCIII, Acción Estratégica en Salud, integrated in the Spanish National R+D+I Plan and financed by ISCIII Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER 'Una manera de hacer Europa') grants PI13/02434, PI16/01861, PI17/01474, PI19/00335, PI19/01240, PI19/01301, PI22/01403, PI22/00258 and the ISCIII national grant PMP22/00022, funded by the European Union (NextGenerationEU). The support of CIBERNED (ISCIII) under the grants CB06/05/2004 and CB18/05/00010. The support from the ADAPTED and MOPEAD projects, European Union/EFPIA Innovative Medicines Initiative Joint (grant numbers 115975 and 115985, respectively); from PREADAPT project, Joint Program for Neurodegenerative Diseases (JPND) grant AC19/00097; from HARPONE project, Agency for Innovation and Entrepreneurship (VLAIO) grant PR067/21 and Janssen. DESCARTES project is funded by German Research Foundation (DFG). Additionally, IdR is supported by the Instituto de Salud Carlos III (ISCIII) under grant FI20/00215. PGG is supported by CIBERNED employment plan (CNV-304-PRF-866). ACF received support from the ISCIII under the grant Sara Borrell (CD22/00125). JEC received support from National Institute of Health award P30AG066546., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Associations of plasma SMOC1 and soluble IL6RA levels with the progression from mild cognitive impairment to dementia

  • Morató, Xavier
  • Puerta, Raquel
  • Cano, Amanda
  • Orellana, Adelina
  • de Rojas, Itziar
  • Capdevila, María
  • Montrreal, Laura
  • Rosende-Roca, Maitée
  • García-González, Pablo
  • Olivé, Claudia
  • García-Gutiérrez, Fernando
  • Blázquez, Josep
  • Miguel, Andrea
  • Núñez-Llaves, Raúl
  • Pytel, Vanesa
  • Alegret, Montserrat
  • Fernández, María Victoria
  • Marquié, Marta
  • Valero, Sergi
  • Cavazos, Jose Enrique
  • Mañes, Santos
  • Boada, Mercè
  • Cabrera-Socorro, Alfredo
  • Ruiz, Agustín
Despite the central role attributed to neuroinflammation in the etiology and pathobiology of Alzheimer's disease (AD), the direct link between levels of inflammatory mediators in blood and cerebrospinal fluid (CSF) compartments, as well as their potential implications for AD diagnosis and progression, remains inconclusive. Moreover, there is debate on whether inflammation has a protective or detrimental effect on disease onset and progression. Indeed, distinct immunological mechanisms may govern protective and damaging effects at early and late stages, respectively. This study aims to (i) identify inflammatory mediators demonstrating robust correlations between peripheral and central nervous system (CNS) compartments by means of plasma and CSF analysis, respectively, and (ii) assess their potential significance in the context of AD and disease progression from mild cognitive impairment (MCI) to dementia. To achieve this, we have examined the inflammatory profile of a well-defined subcohort comprising 485 individuals from the Ace Alzheimer Center Barcelona (ACE). Employing a hierarchical clustering approach, we thoroughly evaluated the intercompartmental correlations of 63 distinct inflammation mediators, quantified in paired CSF and plasma samples, using advanced SOMAscan technology. Of the array of mediators investigated, only six mediators (CRP, IL1RAP, ILRL1, IL6RA, PDGFRB, and YKL-40) exhibited robust correlations between the central and peripheral compartments (proximity scores <400). To strengthen the validity of our findings, these identified mediators were subsequently validated in a second subcohort of individuals from ACE (n = 873). The observed plasma correlations across the entire cohort consistently have a Spearman rho value above 0.51 (n = 1,360, p < 1.77E-93). Of the high CSF-plasma correlated proteins, only soluble IL6RA (sIL6RA) displayed a statistically significant association with the conversion from MCI to dementia. This association remained robust even after applying a stringent Bonferroni correction (Cox proportional hazard ratio [HR] = 1.936 per standard deviation; p = 0.0018). This association retained its significance when accounting for various factors, including CSF amyloid (Aβ42) and Thr181-phosphorylated tau (p-tau) levels, age, sex, baseline Mini-Mental State Examination (MMSE) score, and potential sampling biases identified through principal component analysis (PCA) modeling. Furthermore, our study confirmed the association of both plasma and CSF levels of SPARC-related modular calcium-binding protein 1 (SMOC1) with amyloid and tau accumulation, indicating their role as early surrogate biomarkers for AD pathology. Despite the lack of a statistically significant correlation between SMOC1 levels in CSF and plasma, both acted as independent biomarkers of disease progression (HR > 1.3, p < 0.002). In conclusion, our study unveils that sIL6RA and SMOC1 are associated with MCI progression. The absence of correlations among inflammatory mediators between the central and peripheral compartments appears to be a common pattern, with only a few intriguing exceptions., A. Ruiz received support from the HARPONE project, Agency for Innovation and Entrepreneurship (VLAIO) grant Nº PR067/21 and Jansen; from the PREADAPT project, Joint Program for Neurodegenerative Diseases (JPND) grant Nº AC19/00097; from the ADAPTED project, EU/EFPIA Innovative Medicines Initiative Joint Undertaking grant Nº 115975; from the DESCARTES project, German Research Foundation (DFG); and from Fundación Bancaria“La Caixa”, Fundación Echevarne and Grifols S.A. (GR@ACE project). Research funding support for the analyses was granted to the Ace Alzheimer Center Barcelona (X. Morató and M. Boada) by Novo Nordisk. S. Manes received support from the Spanish Ministry of Science and Innovation (MCIN/AEI/10.13039/501100011033) (grant PID2020-116303RB-I00). The authors acknowledge the support of the Spanish Ministry of Science and Innovation, Proyectos de Generación de Conocimiento grant PID2021-122473OA-I00. Support was also given by Acción Estratégica en Salud, integrated into the Spanish National R +D +I Plan and financed by ISCIII Subdirección General de Evaluaci´ on and Fondo Europeo de Desarrollo Regional (FEDER“Una manera de hacer Europa") grants PI17/01474, PI19/00335, PI22/01403, and PI22/00258 and ISCIII national grant PMP22/00022, funded by the European Union (NextGenerationEU). The support of CIBERNED (ISCIII) under grants CB06/05/ 2004 and CB18/05/00010 is also acknowledged. A. Cano received support from the Instituto de Salud Carlos III (ISCIII) under the grant Sara Borrell (CD22/00125) and from Fundación ADEY (under the program“Proyectos de Investigacioón en Salud 2023”). I. de Rojas was supported by ISCIII under grant FI20/00215. P. García-Gonz´ alez was supported by the CIBERNED employment plan (CNV-304-PRF-866). S. Valero received support from the TARTAGLIA project, the program of the Spanish Ministry of Science and Innovation R&D Missions in Artificial Intelligence, the Spain Digital 2025 Agenda, and the National Artificial Intelligence Strategy, financed by the European Union through Next Generation EU funds, under grant Nº MIA.2021.M02.0005., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Linking genomic and proteomic signatures to brain amyloid burden: insights from GR@ACE/DEGESCO

  • Puerta, Raquel
  • Pérez-Tur, Jordi
  • Bullido, María Jesús
  • Real, Luis Miguel
  • Mir, Pablo
  • Ruiz, Agustín
  • Alzheimer’s Disease Neuroimaging Initiative
27 páginas, 7 figuras, 3 tablas, Alzheimer's disease (AD) is a complex disease with a strong genetic component, yet many genetic risk factors remain unknown. We combined genome-wide association studies (GWAS) on amyloid endophenotypes measured in cerebrospinal fluid (CSF) and positron emission tomography (PET) as surrogates of amyloid pathology, which may provide insights into the underlying biology of the disease. We performed a meta-GWAS of CSF Aβ42 and PET measures combining six independent cohorts (n = 2,076). Given the opposite beta direction of Aβ phenotypes in CSF and PET measures, only genetic signals showing opposite directions were considered for analysis (n = 376,599). We explored the amyloidosis signature in the CSF proteome using SOMAscan proteomics (ACE cohort, n = 1,008), connected it with GWAS loci modulating amyloidosis and performed an enrichment analysis of overlapping hits. Finally, we compared our results with a large meta-analysis using publicly available datasets in CSF (n = 13,409) and PET (n = 13,116). After filtering the meta-GWAS, we observed genome-wide significance in the rs429358-APOE locus and annotated nine suggestive hits. We replicated the APOE loci using the large CSF-PET meta-GWAS, identifying multiple AD-associated genes including the novel GADL1 locus. Additionally, we found 1,387 FDR-significant SOMAscan proteins associated with CSF Aβ42 levels. The overlap among GWAS loci and proteins associated with amyloid burden was minimal (n = 35). The enrichment analysis revealed mechanisms connecting amyloidosis with the plasma membrane's anchored component, synapse physiology and mental disorders that were replicated in the large CSF-PET meta-analysis. Combining CSF and PET amyloid GWAS with CSF proteome analyses may effectively elucidate causative molecular mechanisms behind amyloid mobilization and AD physiopathology., The Genome Research @ Ace Alzheimer Center Barcelona project (GR@ACE) is supported by Grifols SA, Fundación bancaria ‘La Caixa’, Ace Alzheimer Center Barcelona and CIBERNED. Ace Alzheimer Center Barcelona is one of the participating centers of the Dementia Genetics Spanish Consortium (DEGESCO). The FACEHBI study is supported by funds from Ace Alzheimer Center Barcelona, Grifols, Life Molecular Imaging, Araclon Biotech, Alkahest, Laboratorio de análisis Echevarne and IrsiCaixa. Authors acknowledge the support of the Spanish Ministry of Science and Innovation, Proyectos de Generación de Conocimiento grants PID2021-122473OA-I00, PID2021-123462OB-I00 and PID2019-106625RB-I00. ISCIII, Acción Estratégica en Salud, integrated in the Spanish National R + D + I Plan and financed by ISCIII Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER “Una manera de hacer Europa") grants PI13/02434, PI16/01861, PI17/01474, PI19/00335, PI19/01240, PI19/01301, PI22/01403, PI22/00258 and the ISCIII national grant PMP22/00022, funded by the European Union (NextGenerationEU). The support of CIBERNED (ISCIII) under the grants CB06/05/2004 and CB18/05/00010. The support from the ADAPTED and MOPEAD projects, European Union/EFPIA Innovative Medicines Initiative Joint (grant numbers 115975 and 115985, respectively); from PREADAPT project, Joint Program for Neurodegenerative Diseases (JPND) grant Nº AC19/00097; from HARPONE project, Agency for Innovation and Entrepreneurship (VLAIO) grant Nº PR067/21 and Janssen. DESCARTES project is funded by German Research Foundation (DFG). Additionally, AR is also supported by STAR Award. University of Texas System. Tx, United States, The South Texas ADRC. National Institute of Aging. National Institutes of Heath. USA. (P30AG066546) and the Keith M. Orme and Pat Vigeon Orme Endowed Chair in Alzheimer’s and Neurodegenerative Diseases. IdR is supported by the Instituto de Salud Carlos III (ISCIII) under grant FI20/00215. PGG is supported by CIBERNED employment plan (CNV-304-PRF-866). ACF received support from the ISCIII under the grant Sara Borrell (CD22/00125). JEC received support from National Institute of Health award P30AG066546., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A Spanish-Portuguese GWAS of progressive supranuclear palsy reveals a novel risk locus in NFASC

  • García-González, Pablo
  • Díaz Belloso, Rafael
  • Munoz-Delgado, Laura
  • Buiza Rueda, Dolores
  • Gómez-Garre, Pilar
  • Pérez-Tur, Jordi
  • Real, Luis M.
  • Bullido, María Jesús
  • Ruiz, Agustín
18 páginas, 2 figuras, Progressive supranuclear palsy (PSP) is a rare 4-repeat tauopathy that causes behavioural, movement and cognitive abnormalities. We genotyped all available clinical and histopathological PSP cases in Spain and Portugal (N = 522), and conducted the largest PSP GWAS of the Iberian population to date. Genetic burden analysis revealed reduced diagnostic specificity in clinically diagnosed atypical PSP cases-when applying the 2017 MDS criteria-compared to Richardson's syndrome cases. We independently replicated eight PSP risk variants in seven known loci (MAPT, MOBP, EIF2AK3, STX6, SLCO1A2, DUSP10 and APOE), and identified a novel locus in NFASC/CNTN2 (rs12744678 C: OR[95%CI] = 0.83[0.78-0.89]; p = 4.15·10-08) after meta-analysis with a newly available Dutch cohort and publicly available summary statistics (3,099 PSP; 11,482 controls). Enrichment analysis and protein expression profiling highlighted oligodendrocyte function and myelination as likely contributors to PSP pathogenesis. Our findings broaden the genetic landscape of PSP and suggest potential therapeutic avenues focused on modulating neuron-oligodendrocyte interactions., This work was funded by CIBERNED (Centro Investigación Biomédica en Red Enfermedades Neurodegenerativas) 10th internal call for cooperative projects (Register number: 2019/09). Agustín Ruiz, Pascual Sanchez-Juan, Alberto Rábano, and Maria J. Bullido received funding from this convocatory. Pablo García-González received support by CIBERNED employment plan CNV-304-PRF-866. CIBERNED is integrated into ISCIII (Instituto de Salud Carlos III). Mercé Boada, Marta Marquié and Agustín Ruiz are also supported by national grants PI13/02434, PI16/01861, PI17/01474, PI19/01240, PI19/01301, PI19/00335 and PI22/011403, and CIBERNED grant 2019/08. The Genome Research @ Fundació ACE project (GR@ACE) is supported by Grifols SA, Fundación bancaria “La Caixa”, Fundació ACE, and CIBERNED. Acción Estratégica en Salud is integrated into the Spanish National R  +  D  +  I Plan and funded by ISCIII—Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER—“Una manera de hacer Europa”). Agustín Ruiz is supported by ISCIII national grant PMP22/00022, funded by the European Union (NextGenerationEU). He is also supported by the STAR Award. University of Texas System. Tx, United States, The South Texas ADRC. National Institute of Aging. National Institutes of Health. USA. (P30AG066546), the Keith M. Orme and Pat Vigeon Orme Endowed Chair in Alzheimer’s and Neurodegenerative Diseases (2024-2025) and Patricia Ruth Frederick Distinguished Chair for Precision Therapeutics in Alzheimer’s and Neurodegenerative Diseases (2025-2028). The genotyping service to generate GR@ACE and PSP/DEGESCO GWAS data was carried out at CEGEN-PRB3-ISCIII; it is supported by grant PT17/0019, of the PE I + D + i 2013-2016, funded by ISCIII and ERDF”. Itziar de Rojas received support by a national grant from ISCIII FI20/00215. Amanda Cano acknowledges the support of the Spanish Ministry of Science, Innovation and Universities under the grant Juan de la Cierva (FJC2018-036012-I), the support of ISCIII under the grant Sara Borrell (CD22/00125), Spanish Ministry of Science and Innovation, Proyectos de Generación de Conocimiento grant PID2021-122473OA-I00, and Fundación ADEY under the program “Proyectos de Investigación en Salud 2023”. Fondo de Investigacion en Salud (Instituto Carlos III) (PI17/00096) in the frame of the European Regional Development Fund (ERDF) and to Fundacio ́ la Marato ́ de TV3 (PI043296 and 202009-10). This work was supported by the Spanish Ministry of Science and Innovation (RTC2019-007150-1), the Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union (PI14/01823, PI16/01575, PI18/01898, PI19/01576, PI21/01875), the Consejería de Economía, Innovación, Ciencia y Empleo de la Junta de Andalucía (CVI-02526, CTS-7685, PY20_00896), and the Consejería de Salud y Bienestar Social de la Junta de Andalucía (PI-0471-2013, PE-0210-2018, PI-0459-2018, PE-0186-2019). Pilar Gómez-Garre was supported by the “Nicolás Monardes” program (C-0048-2017) from Andalusian Regional Ministry of Health. Laura Muñoz-Delgado was supported by the “Río Hortega” program [CM21/00051] from the Instituto de Salud Carlos III (ISCIII-FEDER). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Sven J. van der Lee was funded for this study by NWO (#733050512, PROMO-GENODE: a PROspective study of MOnoGEnic causes Of Dementia) a substantial donation by Edwin Bouw Fonds and Dioraphte. SvdL further received funding for the GeneMINDS consortium, which is powered by Health~Holland, Top Sector Life Sciences & Health. Sven J. van der Lee is a recipient of ABOARD, which is a public-private partnership receiving funding from ZonMW (#73305095007) and Health~Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). More than 30 partners participate in ABOARD. ABOARD also receives funding from Edwin Bouw Fonds and Gieskes-Strijbisfonds. ABOARD also receives funding from de Hersenstichting, Edwin Bouw Fonds and Gieskes-Strijbisfonds. Array genotyping was performed in the context of EADB (European Alzheimer DNA biobank) funded by the JPco-fuND FP-829-029 (ZonMW projectnumber 733051061). This work has been supported by the Queen Sofia Foundation. Pascual Sánchez-Juan is supported by grants from ISCIII (PMP22/00022 and PI20/01011) and TED2021-131676B-100. Luis Miguel Real received support from “The absence of seroconversion after exposition to hepatitis C virus is not related to KIR-HLA genotype combinations” (GEHEP-012 study). Consejería de Salud de la Junta de Andalucía (grant number PI-0001/2017) and CIBERINFEC -Consorcio Centro de Investigación Biomédica en Red de Enfermedades Infecciosas- Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación y Unión Europea (Spain) (NextGeneration EU) (grant number CB21/13/00118). Jose Luis Royo received support from Project 23.04.2021 from Santángela Foundation (Sevilla, Spain)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

GWAS meta-analysis of cerebrospinal fluid Alzheimer's biomarkers reveals loci regulating lipids, brain volume and autophagy

  • Timsina, Jigyasha
  • Pérez-Tur, Jordi
  • Bullido, María Jesús
  • Mir, Pablo
  • Navarro, Arcadi
  • Cruchaga, Carlos
24 páginas, 4 figuras, 3 tablas., Cerebrospinal fluid amyloid beta 42, total tau, and phosphorylated tau 181 are well accepted markers of Alzheimer's disease. These biomarkers better reflect disease pathogenesis compared to clinical diagnosis. Here, we perform a genome wide association study meta-analysis including 18,948 individuals of European ancestry and identify 12 genome-wide significant loci across all three biomarkers, eight of them novel. We replicate the association of biomarkers with APOE, CR1, GMNC/CCDC50 and C16orf95/MAP1LC3B. Novel loci include BIN1 for amyloid beta and GNA12, MS4A6A, SLCO1A2 with both total tau and phosphorylated tau 181, as well as additional loci on chr. 8, near ANGPT1 and chr. 9 near SMARCA2. We also demonstrate that these variants have significant association with Alzheimer's disease risk, disease progression and/or brain amyloidosis. The associated genes are implicated in lipid metabolism independent of APOE, coupled with autophagy and brain volume regulation driven by total tau and phosphorylated tau 181 dysregulation., We thank the Valdecilla Biobank (PT17/0015/0019), integrated into the Spanish BiobankNetwork, for their support and collaboration in sample collection and management. We want to acknowledge support from Moondance Dementia Research Laboratory. Spanish Institute of Health Carlos III (ISCIII). Also, the Spanish Ministry of Science and Innovation, Proyectos de Generación de Conocimiento grant PID2021-122473OA-I00, Instituto de Salud Carlos III (ISCIII), Acción Estratégica en Salud integrated in the Spanish National R + D + I Plan and financed by ISCIII Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER “Una manera de hacer Europa”) grants PI19/00335 and PI22/01403. The support of CIBERNED (ISCIII) under the grant CB18/05/00010. The support from PREADAPT project, Joint Program for Neurodegenerative Diseases (JPND) grant No AC19/00097. The support of Fundación Bancaria “La Caixa”, Fundación ADEY, Fundación Echevarne and Grífols SA (GR@ACE project). A.C. received support from the ISCIII under the grant Sara Borrell (CD22/00125). P.G.G. is supported by CIBERNED employment plan (CNV-304-PRF-866). MB received funding from CIBERNED (Instituto de Salud Carlos III (ISCIII); EU/EFPIA Innovative Medicines Initiative Joint Undertaking, ADAPTED Grant No. 115975; EXIT project, EU Euronanomed3 Program JCT2017 Grant No. AC17/00100; MOPEAD, Innovative Medicine Initiative, Grant. N°. 115985; PreDADQoL, ERA-NET (call 2015). Grant n° AC15/00082; TARTAGLIA (Red federada para accelerar la aplicación de la inteligencia artificial en el sistema sanitario español); PREADAPT project, Joint Program for Neurodegenerative Diseases (JPND) Grant No. AC19/00097; GECONEU Grant No. 2023-1-ELO1-KAZZ0-HED-000032173 co –founded by the European Union; Grants PI13/02434, PI16/01861, BA19/00020, and PI19/01301 from the Acción Estratégica en Salud, integrated in the Spanish National RCDCI Plan and financed by Instituto de Salud Carlos III (ISCIII)- Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER – “Una manera de Hacer Europa”); Fundació “La Caixa” and Grífols (GR@ACE project); and Proyectos de Investigación de Medicina Personalizada (ISCIII), PMP-DEGESCO,Grant N° PMP22/00022. Marta Marquié received funding support from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement no. 796706 and the Instituto de Salud Carlos III (ISCIII) Acción Estratégica en Salud, integrated in the Spanish National RCDCI Plan and financed by ISCIII-Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER - Una manera de hacer Europa) grant PI19/00335. F.A. receives funding from the JDC2022-049347-I grant, funded by the MCIU/AEI/10.13039/ 501100011033 and the European Union NextGenerationEU/PRTR. N.V.-T. receives funding from the Spanish Research Agency MICIU/AEI/ 10.13039/501100011033 (grant RYC2022-038136-I cofunded by the European Union FSE+, and grant PID2022-143106OA-I00 cofunded by the European Union FEDER)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Harnessing acoustic speech parameters to decipher amyloid status in individuals with mild cognitive impairment

  • García-Gutiérrez, Fernando
  • Hinzen, Wolfram
  • Valero, Sergi
Alzheimer's disease (AD) is a neurodegenerative condition characterized by a gradual decline in cognitive functions. Currently, there are no effective treatments for AD, underscoring the importance of identifying individuals in the preclinical stages of mild cognitive impairment (MCI) to enable early interventions. Among the neuropathological events associated with the onset of the disease is the accumulation of amyloid protein in the brain, which correlates with decreased levels of Aß42 peptide in the cerebrospinal fluid (CSF). Consequently, the development of non-invasive, low-cost, and easy-to-administer proxies for detecting Aß42 positivity in CSF becomes particularly valuable. A promising approach to achieve this is spontaneous speech analysis, which combined with machine learning (ML) techniques, has proven highly useful in AD. In this study, we examined the relationship between amyloid status in CSF and acoustic features derived from the description of the Cookie Theft picture in MCI patients from a memory clinic. The cohort consisted of fifty-two patients with MCI (mean age 73 years, 65% female, and 57% positive amyloid status). Eighty-eight acoustic parameters were extracted from voice recordings using the extended Geneva Minimalistic Acoustic Parameter Set (eGeMAPS), and several ML models were used to classify the amyloid status. Furthermore, interpretability techniques were employed to examine the influence of input variables on the determination of amyloid-positive status. The best model, based on acoustic variables, achieved an accuracy of 75% with an area under the curve (AUC) of 0.79 in the prediction of amyloid status evaluated by bootstrapping and Leave-One-Out Cross Validation (LOOCV), outperforming conventional neuropsychological tests (AUC = 0.66). Our results showed that the automated analysis of voice recordings derived from spontaneous speech tests offers valuable insights into AD biomarkers during the preclinical stages. These findings introduce novel possibilities for the use of digital biomarkers to identify subjects at high risk of developing AD., This project has received funding from R&D Missions in the Artificial Intelligence program, which is part of the Spain Digital 2025 Agenda and the National Artificial Intelligence Strategy and financed by the European Union through Next Generation EU funds (project TARTAGLIA, exp. MIA.2021.M02.0005). This project has also received funding from the Instituto de Salud Carlos III (ISCIII) Acción Estratégica en Salud, integrated in the Spanish National RCDCI Plan and financed by ISCIII Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER - Una manera de hacer Europa) grant PI19/00335 awarded to MM, grant PI17/01474 awarded to MB, grants AC17/00100, PI19/01301, and PI22/01403 awarded to AR and by the European Union Joint Programme-Neurodegenerative Disease Research (JPND) Multinational research projects on Personalized Medicine for Neurodegenerative Diseases/Instituto de Salud Carlos III grant AC19/00097 awarded to AR and grant FI20/00215 from the Instituto de Salud Carlos III (ISCIII) awarded to IR. For CSF biomarker research, AR and MB received support from the European Union/EFPIA Innovative Medicines Initiative Joint undertaking ADAPTED and MOPEAD projects (grant numbers 115975 and 115985, respectively). AC received support from the Instituto de Salud Carlos III (ISCIII) under the grant Sara Borrell (CD22/00125) and the Spanish Ministry of Science and Innovation, Proyectos de Generación de Conocimiento grant PID2021-122473OA-I00.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Plasma extracellular vesicles reveal early molecular differences in amyloid positive patients with early-onset mild cognitive impairment

  • Cano, Amanda|||0000-0001-9567-4283
  • Esteban de Antonio, Ester|||0000-0003-1965-6010
  • Bernuz, Mireia|||0000-0002-2052-6902
  • Puerta, Raquel|||0000-0002-1191-5893
  • García-González, Pablo|||0000-0003-0125-5403
  • De Rojas, Itziar|||0000-0002-2148-381X
  • Olivé Roig, Clàudia|||0000-0002-9438-5639
  • Pérez-Cordón, Alba|||0000-0002-6028-0791
  • Montrreal Navarro, Laura|||0000-0002-0010-645X
  • Núñez-Llaves, Raúl|||0000-0002-6702-4774
  • Sotolongo Grau, Oscar|||0000-0002-9679-0670
  • Alarcón-Martín, Emilio|||0000-0002-0985-872X
  • Valero, Sergi|||0000-0002-6599-948X
  • Alegret, Montserrat|||0000-0002-8164-9500
  • Martín, Elvira
  • Martino-Adami, Pamela V.
  • Ettcheto, Miren|||0000-0002-4301-7297
  • Camins, Antoni|||0000-0002-1229-5956
  • Vivas, Assumpta
  • Gómez Chiari, Marta|||0000-0001-6726-1721
  • Tejero, Miguel Ángel
  • Orellana del Río, Adelina|||0000-0002-0204-1944
  • Tárraga, Lluís|||0000-0002-8423-946X
  • Marquié, Marta|||0000-0002-0660-0950
  • Ramirez, Alfredo|||0000-0003-4991-763X
  • Martí, Mercè|||0000-0002-1846-0043
  • Pividori, María Isabel|||0000-0002-5266-7873
  • Boada, Mercè|||0000-0003-2617-3009
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
In the clinical course of Alzheimer's disease (AD) development, the dementia phase is commonly preceded by a prodromal AD phase, which is mainly characterized by reaching the highest levels of Aβ and p-tau-mediated neuronal injury and a mild cognitive impairment (MCI) clinical status. Because of that, most AD cases are diagnosed when neuronal damage is already established and irreversible. Therefore, a differential diagnosis of MCI causes in these prodromal stages is one of the greatest challenges for clinicians. Blood biomarkers are emerging as desirable tools for pre-screening purposes, but the current results are still being analyzed and much more data is needed to be implemented in clinical practice. Because of that, plasma extracellular vesicles (pEVs) are gaining popularity as a new source of biomarkers for the early stages of AD development. To identify an exosome proteomics signature linked to prodromal AD, we performed a cross-sectional study in a cohort of early-onset MCI (EOMCI) patients in which 184 biomarkers were measured in pEVs, cerebrospinal fluid (CSF), and plasma samples using multiplex PEA technology of Olink© proteomics. The obtained results showed that proteins measured in pEVs from EOMCI patients with established amyloidosis correlated with CSF p-tau181 levels, brain ventricle volume changes, brain hyperintensities, and MMSE scores. In addition, the correlations of pEVs proteins with different parameters distinguished between EOMCI Aβ( +) and Aβ(-) patients, whereas the CSF or plasma proteome did not. In conclusion, our findings suggest that pEVs may be able to provide information regarding the initial amyloidotic changes of AD. Circulating exosomes may acquire a pathological protein signature of AD before raw plasma, becoming potential biomarkers for identifying subjects at the earliest stages of AD development.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Extracellular vesicles, the emerging mirrors of brain physiopathology

  • Cano, Amanda|||0000-0001-9567-4283
  • Ettcheto, Miren|||0000-0002-4301-7297
  • Bernuz, Mireia|||0000-0002-2052-6902
  • Puerta, Raquel|||0000-0002-1191-5893
  • Esteban de Antonio, Ester|||0000-0003-1965-6010
  • Sánchez-López, Elena|||0000-0003-2571-108X
  • Souto, Eliana B.
  • Camins, Antoni|||0000-0002-1229-5956
  • Martí, Mercè|||0000-0002-1846-0043
  • Pividori, María Isabel|||0000-0002-5266-7873
  • Boada, Mercè|||0000-0003-2617-3009
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
Extracellular vesicles are secreted by a wide variety of cells, and their primary functions include intercellular communication, immune responses, human reproduction, and synaptic plasticity. Their molecular cargo reflects the physiological processes that their cells of origin are undergoing. Thus, many studies have suggested that extracellular vesicles could be a promising biomarker tool for many diseases, mainly due to their biological relevance and easy accessibility to a broad range of body fluids. Moreover, since their biological composition leads them to cross the blood-brain barrier bidirectionally, growing evidence points to extracellular vesicles as emerging mirrors of brain diseases processes. In this regard, this review explores the biogenesis and biological functions of extracellular vesicles, their role in different physiological and pathological processes, their potential in clinical practice, and the recent outstanding studies about the role of exosomes in major human brain diseases, such as Alzheimer's disease (AD), Parkinson's disease (PD), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or brain tumors.